Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
Answer from: Medical Oncologist at Academic Institution
This is a good question and is not a rare situation in the management of HER2+ metastatic breast cancer. Radiographic complete response occurs with first-line treatment in 6-15% (CLEOPATRA, GIM-14, and other trials). Currently, the standard of care is to continue anti-Her2 therapy indefinitely. Howe...
Comments
Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology Thank you. Do you know if ctDNA is being looked at...
Medical Oncologist at UC San Diego School of Medicine I have done this in 2 patients who have been in co...
Thank you. Do you know if ctDNA is being looked at...
I have done this in 2 patients who have been in co...